"Given the evidence base available to us currently, can we claim pretomanid a victory? We think more research is needed before pretomanid can be celebrated as a promising treatment for people with tuberculosis."
A comment, authored by Lindsay McKenna, Treatment Action Group and Jennifer Furin, Department of Global Health and Social Medicine, Harvard Medical School, reflects on the results from the TB Alliance's phase IIb study evaluating BPaZ for drug-susceptible TB (compared to HRZE) and BPaMZ for multidrug-resistant TB, published in The Lancet Respiratory Medicine.
BPaZ - bedaquiline, pretomanid and pyrazinamide
HRZE - oral isoniazid, rifampicin, pyrazinamide and ethambutol
BPaMZ - bedaquiline, pretomanid, moxifloxacin and pyrazinamide